<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220116053739N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-15</date_registration>
      <primary_sponsor>Shahre-kord University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the clinical course and consequences of disease in the children suspicious to Covid-19 who have/have not received Antibiotics</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the clinical course and consequences of disease in the children suspicious to Covid-19 who have/have not received Antibiotics</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-28</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61358</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The participants have been randomly distributed to the control and experimental groups using Random Allocation Software, Blinding description: In selecting the envelopes, neither the participant nor the researcher is not aware of the envelope content and an envelope is randomly selected for each patient. After selecting an envelope, the parents of the patient are informed if the patient had received Antibiotic or not. Even the researcher was not informed of that.
The number of participants in the study was considered to be envelopes with numbers 1 to 70 and using the software, the number 0 or 1 was randomly assigned to each envelope, and the number zero means not receiving antibiotics and the number 1 It means taking antibiotics.</study_design>
      <phase>3</phase>
      <hc_freetext>Covid-19.</hc_freetext>
      <i_freetext>Intervention 1: Patients in the intervention group were treated with a group of antibiotics with gram-negative and gram-positive coverage (third generation cephalosporin). Third-generation cephalosporins include cefotaxime (from Eixir Pharmaceutical Company) as an injection at a dose of 50 mg per kg every 8 hours for at least 7 days. Also in this group, the routine hospital care intervention intended for the control group included serum therapy (including normal saline serum, one-third and two-thirds serum), and the use of antipyretics (acetaminophen at a dose of 10 mg per kg). It was administered orally or by injection in patients with a body temperature of more than 38 with an interval of at least 6 hours. Intervention 2: In the control group, patients did not receive any antibiotics and routine hospital care included serum therapy (including normal saline, one-third and two-thirds serum), and the use of antipyretics (acetaminophen at a dose of 10 mg per kg). Received orally or by injection in patients with a body temperature greater than 38 (at least 6 hours apart) during hospitalization.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is After analyzing the results, a decision will be made on this issue</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Mohsenifar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Somaheh Blvd.</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8814873588</zip>
        <telephone>0983833335833</telephone>
        <email>amin_mohsenifar@outlook.com</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nabiollah Asadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Parastar Street</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8815713471</zip>
        <telephone>+98 38 3333 0061</telephone>
        <email>n.asadpour@skums.ac.ir</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patient with IgM positive
The patient with confirmed molecular test</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having the background of Underlying disease
Any clinical or laboratory evidence of the patient need for Antibiotics
Lack of consent of the patient and his/her family for the participation in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>U07.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Covid 19</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Patients in the intervention group were treated with a group of antibiotics with gram-negative and gram-positive coverage (third generation cephalosporin). Third-generation cephalosporins include cefotaxime (from Eixir Pharmaceutical Company) as an injection at a dose of 50 mg per kg every 8 hours for at least 7 days. Also in this group, the routine hospital care intervention intended for the control group included serum therapy (including normal saline serum, one-third and two-thirds serum), and the use of antipyretics (acetaminophen at a dose of 10 mg per kg). It was administered orally or by injection in patients with a body temperature of more than 38 with an interval of at least 6 hours.</i_keyword>
      <i_keyword>In the control group, patients did not receive any antibiotics and routine hospital care included serum therapy (including normal saline, one-third and two-thirds serum), and the use of antipyretics (acetaminophen at a dose of 10 mg per kg). Received orally or by injection in patients with a body temperature greater than 38 (at least 6 hours apart) during hospitalization.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Duration of hospitalization. Timepoint: Time of discharge from the hospital. Method of measurement: Number of days hospitalized.</prim_outcome>
      <prim_outcome>Complete blood count (CBC). Timepoint: Day of hospitalization, seven days after hospitalization. Method of measurement: Use of cell counting machine.</prim_outcome>
      <prim_outcome>Fever. Timepoint: Day of hospitalization, seven days after hospitalization and One month after hospitalization. Method of measurement: Thermometer.</prim_outcome>
      <prim_outcome>Cough. Timepoint: Day of hospitalization, seven days after hospitalization and One month after hospitalization. Method of measurement: Asking the patient.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Test result of Troponin. Timepoint: Day of hospitalization and seven days after hospitalization. Method of measurement: Troponin test kit.</sec_outcome>
      <sec_outcome>D-dimer. Timepoint: Day of hospitalization and seven days after hospitalization. Method of measurement: Latex agglutination test.</sec_outcome>
      <sec_outcome>Erythrocyte Sedimentation Rate (ESR). Timepoint: Day of hospitalization and seven days after hospitalization. Method of measurement: The Westergren method.</sec_outcome>
      <sec_outcome>C-reactive protein test (CRP). Timepoint: Day of hospitalization and seven days after hospitalization. Method of measurement: Latex agglutination test.</sec_outcome>
      <sec_outcome>Anorexia. Timepoint: Day of hospitalization, seven days after hospitalization and One month after hospitalization. Method of measurement: Asking the patient.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahrekord University Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-28</approval_date>
        <contact_name>Ethics Committee of Shahrekord University of Medical Sciences</contact_name>
        <contact_address>somaheh Blvd. shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
